Home / Stocks / KRYS

Krystal Biotech (KRYS, Biotechnology) Stock Valuation & Fair Value Quality business with a solid forward outlook

Krystal Biotech (KRYS, Biotechnology) trades at a blended P/E of 47.6, about 65% below its historical normal valuation, with a forward growth estimate of 34.8% and a PEG of 1.37. Analysts' one-year estimates have been hit 38% of the time.

DATA AS OF 2026-08-28
Blended P/E
47.6
Normal P/E
135.5
PEG
1.37
Fwd growth
34.8%
Div yield
0.0%
RSI (14)
54.8
Neutral

The Street vs SeerForecast

Wall Street's mean price target for KRYS is $385.00 across 8 analysts, 9.5% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: quality business with a solid forward outlook. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from significantly overvalued (2026-06-14) to quality business with a solid forward outlook (2026-08-28).

Price and rating by weekClose moved +9.0 percent from 2026-06-14 to 2026-08-24, with 3 rating changes over 21 recorded weeks.2026-06-14: Significantly overvalued, close 317.97 (recalculated)2026-06-16: Significantly overvalued, close 323.37 (recalculated)2026-06-21: Significantly overvalued, close 348.06 (recalculated)2026-07-02: Significantly overvalued, close 375.07 (recalculated)2026-07-06: Significantly overvalued, close 374.68 (recalculated)2026-07-09: Significantly overvalued, close 371.24 (recalculated)2026-07-12: Significantly overvalued, close 365.81 (recalculated)2026-07-13: Significantly overvalued, close 363.44 (recalculated)2026-07-14: Significantly overvalued, close 339.43 (recalculated)2026-07-20: Significantly overvalued, close 339.22 (recalculated)2026-07-22: Fairly valued, close 336.80 (recalculated)2026-07-25: Fairly valued, close 335.19 (recalculated)2026-07-27: Fairly valued, close 351.82 (recalculated)2026-07-31: Fairly valued, close 341.12 (recalculated)2026-08-03: Fairly valued, close 341.122026-08-07: Fairly valued, close 326.45 (recalculated)2026-08-10: Trading above fair value, close 326.452026-08-14: Trading above fair value, close 332.27 (recalculated)2026-08-17: Quality business with a solid forward outlook, close 332.272026-08-21: Quality business with a solid forward outlook, close 346.58 (recalculated)2026-08-24: Quality business with a solid forward outlook, close 346.583183472026-06-142026-08-24
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-14P/E 36.9-73%Significantly overvalued
2026-06-16P/E 36.9-73%Significantly overvalued
2026-06-21P/E 36.9-73%Significantly overvalued
2026-07-02P/E 36.9-73%Significantly overvalued
2026-07-06P/E 36.9-73%Significantly overvalued
2026-07-09P/E 36.9-73%Significantly overvalued
2026-07-12P/E 36.9-73%Significantly overvalued
2026-07-13P/E 36.9-73%Significantly overvalued
2026-07-14P/E 36.9-73%Significantly overvalued
2026-07-20P/E 36.9-73%Significantly overvalued
2026-07-22P/E 47.4-65%Fairly valued
2026-07-25P/E 47.4-65%Fairly valued
2026-07-27P/E 47.4-65%Fairly valued
2026-07-31P/E 47.4-65%Fairly valued
2026-08-03P/E 47.6-65%Fairly valued
2026-08-07P/E 47.6-65%Fairly valued
2026-08-10P/E 45.5-66%Trading above fair value
2026-08-14P/E 45.5-66%Trading above fair value
2026-08-17P/E 45.7-66%Quality business with a solid forward outlook
2026-08-21P/E 45.7-66%Quality business with a solid forward outlook
2026-08-24P/E 47.6-65%Quality business with a solid forward outlook
2026-08-27P/E 47.6-65%Quality business with a solid forward outlook
2026-08-28P/E 47.6-65%Quality business with a solid forward outlook ← now

Frequently asked questions

Is Krystal Biotech stock overvalued?

At a blended P/E of 47.6 versus its historical normal P/E of 135.5, Krystal Biotech trades about 65% below its typical valuation, with a PEG of 1.37 on 34.8% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is Krystal Biotech's fair value and PEG?

Krystal Biotech trades at a blended P/E of 47.6 against a historical normal P/E of 135.5, a PEG of 1.37, and a forward growth estimate of 34.8%.

Has tickerseer's rating of Krystal Biotech changed?

tickerseer's rating moved from significantly overvalued (2026-06-14) to quality business with a solid forward outlook (2026-08-28).

What is the analyst price target for Krystal Biotech?

The mean Wall Street price target for Krystal Biotech is $385.00 across 8 analysts, 9.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track KRYS free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.